多家公募提示信创主题ETF投资风险；又有QDII基金增聘境外投资顾问丨天赐良基早参

Group 1 - The total dividend amount of public funds in 2023 has reached 88.9 billion yuan, which is 1.4 times that of the same period last year, marking a three-year high with over 2,500 distributions [1] - Equity funds are increasingly distributing dividends, with ETFs being prominent in the distribution rankings, such as Huaxia CSI 300 ETF with 2.683 billion yuan and Jiashi CSI 300 ETF with 2.435 billion yuan [1] - Several ETFs have also exceeded 1 billion yuan in dividend distributions this year, including E Fund CSI 300 ETF and Southern CSI 500 ETF [1] Group 2 - Penghua Fund has appointed Italian firm Eurizon Capital as an overseas investment advisor for its global high-yield bond fund and US real estate fund, enhancing service for investors [2] - Eurizon Capital, a shareholder of Penghua Fund, had an asset management scale of 390.5 billion euros as of September last year, operating in 25 countries [2] - The trend of QDII funds hiring experienced overseas advisors is growing, with many having over 15 years of industry experience [2] Group 3 - Dongfanghong Asset Management announced the early closure of its core value mixed fund, which is the first floating fee rate fund in the market, with a planned fundraising cap of 2 billion yuan [3][4] - The fund was subscribed with 10 million yuan of the company's own capital [3] Group 4 - Several public funds, including Fuguo Fund and Guotai Fund, have warned investors about risks associated with the recent volatility in the information technology innovation theme ETFs, which have seen a significant increase in scale [5] - As of June 3, the total scale of seven innovation theme ETFs reached 2.544 billion yuan, up over 110% from 1.188 billion yuan on May 23 [5] Group 5 - The Hong Kong innovative drug sector has gained significant attention, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index rising over 51% year-to-date [6] - Multiple innovative drug and healthcare ETFs have also seen year-to-date increases exceeding 40%, outperforming gold stock ETFs which rose 36% [7] Group 6 - Investment opportunities in the medical AI sector are concentrated in three main areas: AI drug development, AI in medical diagnostics and treatment, and the production and application of medical data [8] - The application of AI in drug development is expected to enhance efficiency, with several AI-selected drugs entering clinical validation [8] Group 7 - On June 5, the market experienced a rebound, with the Shanghai Composite Index rising 0.23% and the Shenzhen Component Index increasing by 0.58% [9] - The total trading volume in the Shanghai and Shenzhen markets reached 1.29 trillion yuan, an increase of 137.4 billion yuan from the previous trading day [9] - The information technology sector led the gains, with the information technology ETF rising by 3.98% [9]